O'Reilly S, Donehower R C, Rowinsky E K, Ord S, Grochow L B
Division of Pharmacology and Experimental Therapeutics, Johns Hopkins Oncology Center, Baltimore, MD 21287-8934, USA.
Anticancer Drugs. 1996 Jun;7(4):410-4. doi: 10.1097/00001813-199606000-00006.
Because currently available chemotherapeutic agents are largely ineffective in the treatment of pancreatic cancer, novel treatments are urgently needed to improve outcomes in this disease. The purpose of this phase II study was to evaluate the anti-tumor activity of topotecan, a hydrophilic camptothecin analog that has demonstrated a wide range of anti-tumor activity in preclinical and phase I studies. Topotecan was administered as a 30 min infusion at a dose of 1.5 mg/m2/day for five consecutive days every 3 weeks, to chemotherapy-naive patients with advanced pancreatic cancer. Neutropenia was the principal toxicity of topotecan on this dosing schedule. No significant anti-tumor responses were observed in 27 patients with measurable disease. The median time to disease progression was 7 weeks and the median survival duration was 17.5 weeks. Thus, topotecan, administered on this schedule, is ineffective for patients with pancreatic carcinoma.
由于目前可用的化疗药物在治疗胰腺癌方面大多无效，因此迫切需要新的治疗方法来改善该疾病的治疗效果。这项II期研究的目的是评估拓扑替康的抗肿瘤活性，拓扑替康是一种亲水性喜树碱类似物，在临床前和I期研究中已显示出广泛的抗肿瘤活性。拓扑替康以1.5mg/m²/天的剂量连续输注30分钟，连续五天，每3周给药一次，用于未接受过化疗的晚期胰腺癌患者。中性粒细胞减少是拓扑替康在此给药方案下的主要毒性。在27例可测量疾病的患者中未观察到明显的抗肿瘤反应。疾病进展的中位时间为7周，中位生存期为17.5周。因此，按此方案给药的拓扑替康对胰腺癌患者无效。
